Dr. Lal PathLabs is one of India’s leading diagnostic service providers, offering a wide range of pathology tests and healthcare services. Known for its reliability and accuracy, the company operates a vast network of laboratories and collection centers across India. With a focus on high-quality medical diagnostics and customer satisfaction, Dr. Lal PathLabs plays a key role in helping individuals manage their health and well-being. As of December 5, 2024, the Dr Lal PathLabs share price on the BSE is ₹2972. Below are the projected Dr Lal PathLabs share price targets for the years 2025, 2030, 2035 And 2040.
Additionally, feel free to join our – Tele-(g)ram) where we share Fast stock market news and updates➥https://bit.ly/TradeWatch360
Dr Lal PathLabs Company Overview
Founded in 1949 and headquartered in New Delhi, Dr. Lal PathLabs is a pioneer in the diagnostic services industry. The company provides a comprehensive suite of laboratory tests, including routine tests, specialized tests, health checkups, and screenings, serving both individual patients and healthcare institutions. Its services cover a wide array of specialties such as clinical pathology, microbiology, biochemistry, and molecular diagnostics.
| Company type | Public |
| Traded as | BSE: 539524 NSE: LALPATHLAB |
| Industry | Healthcare |
| Founded | 1949 |
| Founder | S. K. Lal |
| Headquarters | Delhi, India |
| Number of locations | 233 |
| Key people | Arvind Lal (Chairman) |
| Brands | Swasthfit Sugarnme OncoPro NephroPro |
| Revenue | ₹2,346 crore(FY24) |
| Net income | ₹407 crore(FY24) |
| Total assets | ₹2,598 crore(FY24) |
| Number of employees | 3941 (2019) |
| Website | www.lalpathlabs.com |
Dr Lal PathLabs Share Price Target 2025-2040 Forecast
| Year | Year High Target (₹) | Year Low Target (₹) | Year-End Target (₹) |
| 2024 | ₹3650 | ₹1900 | ₹3250 |
| 2025 | ₹4100 | ₹2200 | ₹3500 |
| 2026 | ₹4650 | ₹2630 | ₹3820 |
| 2027 | ₹5010 | ₹2980 | ₹4450 |
| 2028 | ₹5400 | ₹3220 | ₹4630 |
| 2029 | ₹5750 | ₹3780 | ₹5050 |
| 2030 | ₹6100 | ₹4070 | ₹5580 |
| 2035 | ₹9850 | ₹5100 | ₹8900 |
| 2040 | ₹13600 | ₹7900 | ₹12550 |
Technical Analysis for Dr Lal PathLabs Ltd
Dr Lal PathLabs Share Price Target 2025
| Year | 1st Target | 2nd Target |
| 2025 | 3900 | 4100 |
Dr Lal PathLabs is expected to continue its strong performance in the diagnostics sector in 2025, driven by its extensive network and focus on innovation. The share price is projected to reach a first target of ₹3900 and a second target of ₹4100, reflecting steady growth.
Read More:- Tilaknagar Industries Share Price Target 2025, 2030, 2035, 2040
Dr Lal PathLabs Share Price Target 2026
| Year | 1st Target | 2nd Target |
| 2026 | 4430 | 4650 |
In 2026, the company is anticipated to capitalize on rising healthcare awareness and demand for diagnostic services. The share price is forecasted to achieve a first target of ₹4430 and a second target of ₹4650, supported by its market leadership.
Dr Lal PathLabs Ltd Share Price Target 2027
| Year | 1st Target | 2nd Target |
| 2027 | 4910 | 5010 |
By 2027, the company’s emphasis on technological advancements and expanding service offerings is expected to drive further growth. The share price is predicted to hit ₹4910 for the first target and ₹5010 for the second target.
Dr Lal PathLabs Share Price Target 2028
| Year | 1st Target | 2nd Target |
| 2028 | 5230 | 5400 |
In 2028, Dr Lal PathLabs is likely to strengthen its position in the diagnostics industry through strategic investments and innovation. The share price is projected to reach ₹5230 for the first target and ₹5400 for the second target, showcasing consistent growth.
Dr Lal PathLabs Share Price Target 2029
| Year | 1st Target | 2nd Target |
| 2029 | 5620 | 5750 |
The company is expected to maintain its upward trajectory in 2029, driven by operational efficiency and growing demand for diagnostics. The share price is estimated to achieve a first target of ₹5620 and a second target of ₹5750.
Dr Lal PathLabs Share Price Target 2030
| Year | 1st Target | 2nd Target |
| 2030 | 5950 | 6100 |
By 2030, Dr Lal PathLabs is poised to benefit from its long-term strategies and increasing market penetration. The share price is forecasted to reach ₹5950 for the first target and ₹6100 for the second target, reflecting its robust business model.
Dr. Lal PathLabs Share Price Target 2035
| Year | 1st Target | 2nd Target |
| 2035 | 8700 | 9850 |
Over the next decade, the company’s focus on scaling its operations and leveraging technology is expected to drive significant growth. By 2035, the share price is projected to hit ₹8700 for the first target and ₹9850 for the second target.
Read More:- Medi Assist Healthcare Share Price Target 2025, 2030, 2035, 2040
Dr. Lal PathLabs Share Price Target 2040
| Year | 1st Target | 2nd Target |
| 2040 | 12400 | 13600 |
By 2040, Dr Lal PathLabs is expected to emerge as a leading player in the global diagnostics market, delivering substantial returns for investors. The share price is anticipated to achieve a first target of ₹12400 and a second target of ₹13600, highlighting its long-term growth potential.
Dr. Lal PathLabs Fundamentals
| Metric | Value |
| Market Cap | ₹24,843 Cr |
| P/E Ratio (TTM) | 61.89 |
| P/B Ratio | 12.41 |
| Industry P/E | 71.91 |
| Debt to Equity | 0.10 |
| Return on Equity (ROE) | 20.05% |
| EPS (TTM) | 48.03 |
| Dividend Yield | 0.60% |
| 52 Week High | ₹3650 |
| 52 Week Low | ₹1940 |
| Book Value | 239.48 |
| Face Value | 10 |
Dr. Lal PathLabs Ltd Financial Results
| Value In ₹Cr | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM |
| Sales | 1,581 | 2,087 | 2,017 | 2,227 | 2,346 |
| Expenses | 1,145 | 1,526 | 1,527 | 1,617 | 1,689 |
| Operating Profit | 436 | 561 | 490 | 609 | 658 |
| OPM % | 28% | 27% | 24% | 27% | 28% |
| Other Income | 51 | 52 | 42 | 69 | 79 |
| Interest | 16 | 30 | 38 | 29 | 26 |
| Depreciation | 77 | 108 | 150 | 144 | 143 |
| Profit before tax | 394 | 475 | 344 | 505 | 569 |
| Tax % | 25% | 26% | 30% | 28% | |
| Net Profit | 296 | 350 | 241 | 362 | 407 |
| EPS in Rs | 34.99 | 41.37 | 28.65 | 42.85 | 48.07 |
| Dividend Payout % | 57% | 29% | 21% | 42% |
Dr Lal PathLabs Balance Sheet
| Value In ₹Cr | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 |
| Equity Capital | 83 | 83 | 83 | 83 | 84 |
| Reserves | 1,162 | 1,418 | 1,583 | 1,766 | 1,918 |
| Borrowings + | 150 | 533 | 420 | 247 | 198 |
| Other Liabilities + | 265 | 309 | 297 | 357 | 397 |
| Total Liabilities | 1,661 | 2,343 | 2,383 | 2,454 | 2,598 |
| Fixed Assets + | 447 | 1,369 | 1,305 | 1,228 | 1,189 |
| CWIP | 10 | 15 | 5 | 6 | 1 |
| Investments | 59 | 65 | 150 | 114 | 289 |
| Other Assets + | 1,144 | 893 | 923 | 1,107 | 1,119 |
| Total Assets | 1,661 | 2,343 | 2,383 | 2,454 | 2,598 |
Dr Lal PathLabs Ltd Shareholding Pattern
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
| Promoters | 55.23% | 55.23% | 55.03% | 54.60% | 53.92% |
| FIIs | 26.01% | 23.44% | 24.89% | 26.15% | 26.82% |
| DIIs | 7.52% | 6.83% | 6.56% | 9.40% | 12.60% |
| Government | 0.00% | 0.00% | 0.00% | 0.29% | 0.29% |
| Public | 10.37% | 13.80% | 13.01% | 9.24% | 6.02% |
| Others | 0.87% | 0.70% | 0.51% | 0.32% | 0.33% |
| No. of Shareholders | 68,845 | 1,71,846 | 1,80,163 | 1,46,741 | 1,16,606 |
Dr Lal PathLabs Dividends History
| Announcement Date | Ex-Dividend Date | Dividend Type | Dividend (Rs) |
| 23 Oct, 2024 | 05 Nov, 2024 | Interim | 6.00 |
| 07 Aug, 2024 | 20 Aug, 2024 | Interim | 6.00 |
| 10 May, 2024 | 10 Jun, 2024 | Final | 6.00 |
| 01 Feb, 2024 | 13 Feb, 2024 | Interim | 12.00 |
| 11 May, 2023 | 11 Aug, 2023 | Final | 6.00 |
| 27 Jul, 2023 | 11 Aug, 2023 | Interim | 6.00 |
| 28 Jul, 2022 | 05 Aug, 2022 | Interim | 6.00 |
| 17 May, 2022 | 22 Jun, 2022 | Final | 6.00 |
| 30 Jul, 2021 | 18 Aug, 2021 | Interim | 6.00 |
| 21 May, 2021 | 20 Jul, 2021 | Final | 8.00 |
| 29 Jan, 2021 | 09 Feb, 2021 | Interim | 6.00 |
| 06 Nov, 2020 | 18 Nov, 2020 | Interim | 6.00 |
| 25 Feb, 2020 | 05 Mar, 2020 | Interim | 6.00 |
| 08 Nov, 2019 | 20 Nov, 2019 | Interim | 6.00 |
| 17 May, 2019 | 02 Aug, 2019 | Final | 3.50 |
| 06 Nov, 2018 | 19 Nov, 2018 | Interim | 2.50 |
| 14 May, 2018 | 03 Aug, 2018 | Final | 3.00 |
| 09 Nov, 2017 | 20 Nov, 2017 | Interim | 1.50 |
| 12 May, 2017 | 12 Jul, 2017 | Final | 1.70 |
| 02 Feb, 2017 | 13 Feb, 2017 | Interim | 1.30 |
| 27 May, 2016 | 20 Jul, 2016 | Final | 2.45 |
Dr Lal PathLabs Labs Peers comparison
| Sector: Healthcare | Industry: Healthcare | ||||
| Name | P/E | Mar Cap ₹Cr. | Div Yld% | NP Qtr ₹Cr. | ROCE% |
| Apollo Hospitals | 87.92 | 104038.30 | 0.22 | 395.70 | 15.11 |
| Max Healthcare | 96.63 | 102302.31 | 0.15 | 281.81 | 16.00 |
| Fortis Health. | 78.16 | 53756.80 | 0.14 | 193.08 | 10.34 |
| Global Health | 63.83 | 31156.14 | 0.00 | 130.81 | 19.32 |
| Poly Medicure | 98.20 | 28948.77 | 0.11 | 87.45 | 23.62 |
| Narayana Hrudaya | 34.33 | 26784.53 | 0.30 | 198.80 | 26.54 |
| Dr Lal Pathlabs | 61.75 | 24802.98 | 0.81 | 130.80 | 25.17 |
FAQs
Q1. Dr Lal PathLabs Share Price Target 2025?
Ans: The expected share price target for Dr Lal PathLabs in 2025 is ₹3900 as the first target and ₹4100 as the second target, reflecting steady growth in diagnostics and pathology services.
Q2. Dr Lal PathLabs Labs Share Price Target 2026?
Ans: For 2026, the share price is anticipated to reach ₹4430 as the first target and ₹4650 as the second target, driven by increased demand for diagnostic services and expansion in tier-2 and tier-3 cities.
Q3. Dr Lal PathLabs Share Price Target 2027?
Ans: In 2027, the projected share price is ₹4910 as the first target and ₹5010 as the second target, supported by enhanced operational efficiency and service innovation.
Q4. Dr Lal PathLabs Share Price Target 2028?
Ans: The expected share price targets for 2028 are ₹5230 as the first target and ₹5400 as the second target, highlighting consistent financial performance and market leadership.
Q5. Dr Lal PathLabs Labs Share Price Target 2029?
Ans: For 2029, the share price is projected to reach ₹5620 as the first target and ₹5750 as the second target, reflecting continued growth in revenue and market expansion.
Q6. Dr. Lal PathLabs Share Price Target 2030?
Ans: By 2030, the share price is anticipated to achieve ₹5950 as the first target and ₹6100 as the second target, showcasing sustained growth in the healthcare diagnostics industry.
Q7. Dr. Lal PathLabs Share Price Target 2035?
Ans: For 2035, the share price is expected to reach ₹8700 as the first target and ₹9850 as the second target, driven by strategic investments and long-term market expansion.
Q8. Dr. Lal PathLabs Share Price Target 2040?
Ans: By 2040, the share price is anticipated to reach ₹12400 as the first target and ₹13600 as the second target, reflecting robust long-term growth and dominance in the diagnostics sector.
Q9. Who is the current CEO of Dr. Lal PathLabs?
Ans: The CEO of Dr. Lal PathLabs is Shankha Banerjee, who took over the role on May 21, 2024. Banerjee has been with the company since 2014 and has held various leadership roles, including Chief Growth Officer and COO.
Q10. What is the NSE & BSE code for Dr. Lal PathLabs?
Ans: Dr. Lal PathLabs provides diagnostic services, including blood tests, urine tests, and imaging services across a network of centers in India. The BSE code for Dr. Lal PathLabs is 539524. The NSE symbol for Dr. Lal PathLabs is LALPATHLAB.
TradeWatch360 is a premier platform dedicated to providing real-time insights, trends, and updates in the stock market. It is designed to support both new and seasoned investors by delivering timely and actionable information across a range of asset classes, including stocks, futures, commodities, and global markets.